Clinical trial
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
NCT00141479 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00141479 |
|---|---|
| Title | To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox |
| Official title | A Single-center Safety and Tolerability Study to Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Collaborators | H. Lundbeck A/S Industry Wyeth is now a wholly owned subsidiary of Pfizer |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder |
| Intervention type | Drug |
| Interventions | Bifeprunox |
| Start date | May 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Sep 1, 2005 |
| Last update posted | Jan 16, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: